4 sources checked · 2 source groups included · 2h ago
Still Watching
STAT+: FTC demands Martin Shkreli divest his pharma stocks
Business Insider and STAT News describe the same event in different terms.
1 Left3 Center0 Right
Still watching.Optics is waiting for a cleaner match before calling the split.
STILL WATCHING
As of October 13, 2026 at 3:42 PM, this is how Optics News reads the wording differences in this story.
What happenedThe FTC asked a federal court to hold Martin Shkreli in contempt for violating a court order banning him from working in the pharmaceutical industry.
The headline splitThe left frames it as "FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban". The center frames it as "‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencin...".
Match confidenceMedium confidence. 4 sources across 2 bias buckets. Useful framing signal — check the source list before sharing.
Same-event confidenceMedium
4 sources across 2 bias buckets agree on the event.
Framing confidenceModerate
54/99 — meaningful wording shift across the spectrum.
WHAT EACH SIDE EMPHASIZED
Left / center-leftFTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
Business Insider · Center-left · News report
CenterSTAT+: FTC demands Martin Shkreli divest his pharma stocks
STAT News · Center · News report
Right / center-rightNo matching source in this bucket yet.
Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim
Shkreli was banned from the pharmaceutical industry after a trial found that he organized an illegal scheme to perpetuate a monopoly for the drug Daraprim.
